retatrutide phase 2 obesity nejm 2023 jastreboff Dosing Guide: 1-12 mg Weekly Triple Agonist (2026) Retatrutide Phase 3: 60% Achieved

Interesting back story, useless but interesting

Ideal candidates are individuals who have plateaued on dual-agonists, have significant metabolic disease, or require maximum weight-loss velocity

Growth hormone secretory pattern in non-obese children and adolescents with Prader-Willi syndrome

At ADA 2025, Hanmi will present new findings exploring whether muscle hypertrophic effects also translate into broader metabolic improvements, such as enhanced glycemic control and increased basal metabolic rate

Traders assign 88.5% probability to no 2026 approval because historical precedents and current trial status show insufficient time for data maturation, submission, and agency decision before year-end

doi: 10.4158/EP11169.OR